Concepedia

Tania A. Rozgaja Stallons

TA

Statistics

Publications

4

Citations

144

H-Index

4

Active since

2019

Affiliations

Orano (United States)(Current)

RadioMedix (United States)

Orano (France)

Tania A. Rozgaja Stallons is an author at Orano (United States) specializing in pharmacology, medicine, and therapeutic nuclear medicine.

Publications per year

2019–2024

4

Publications

4

Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model

Tania A. Rozgaja Stallons, Amal Saidi, Izabela Tworowska et al. · Molecular Cancer Therapeutics · 2019 · 76 citations · Full text

, , +17

Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003

Astri Fjelde Maaland, Amal Saidi, Julien Torgue et al. · PLoS ONE · 2020 · 39 citations · Full text

, , +17

Preclinical Investigation of [<sup>212</sup>Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model

Amal Saidi, Tania A. Rozgaja Stallons, Amy G. Wong et al. · Journal of Nuclear Medicine · 2024 · 19 citations · Full text

, , +17

First clinical experience using targeted alpha-emitter therapy with 212Pb-DOTAMTATE (AlphaMedix TM) in patients with SSTR(+) neuroendocrine tumors.

Ebrahim S. Delpassand, Izabela Tworowska, Farah Shanoon et al. · 2019 · 10 citations

, , +17

1–4 of 4